| Year |
Citation |
Score |
| 2022 |
Fehlings M, Kim L, Guan X, Yuen K, Tafazzol A, Sanjabi S, Zill OA, Rishipathak D, Wallace A, Nardin A, Ma S, Milojkovic A, Newell EW, Mariathasan S, Yadav M. Single-cell analysis reveals clonally expanded tumor-associated CD57 CD8 T cells are enriched in the periphery of patients with metastatic urothelial cancer responding to PD-L1 blockade. Journal For Immunotherapy of Cancer. 10. PMID 35981786 DOI: 10.1136/jitc-2022-004759 |
0.302 |
|
| 2020 |
Wu TD, Madireddi S, de Almeida PE, Banchereau R, Chen YJ, Chitre AS, Chiang EY, Iftikhar H, O'Gorman WE, Au-Yeung A, Takahashi C, Goldstein LD, Poon C, Keerthivasan S, de Almeida Nagata DE, ... ... Mariathasan S, et al. Peripheral T cell expansion predicts tumour infiltration and clinical response. Nature. PMID 32103181 DOI: 10.1038/S41586-020-2056-8 |
0.321 |
|
| 2014 |
De Togni P, Goellner J, Ruddle NH, Streeter PR, Fick A, Mariathasan S, Smith SC, Carlson R, Shornick LP, Strauss-Schoenberger J, Russell JH, Karr R, Chaplint DD. Abnormal development of peripheral lymphoid organs in mice deficient in lymphotoxin Journal of Immunology. 192: 2007-2014. DOI: 10.1126/science.8171322 |
0.313 |
|
| 2010 |
Ramanathan S, Dubois S, Gagnon J, Leblanc C, Mariathasan S, Ferbeyre G, Rottapel R, Ohashi PS, Ilangumaran S. Regulation of cytokine-driven functional differentiation of CD8 T cells by suppressor of cytokine signaling 1 controls autoimmunity and preserves their proliferative capacity toward foreign antigens. Journal of Immunology (Baltimore, Md. : 1950). 185: 357-66. PMID 20519645 DOI: 10.4049/Jimmunol.1000066 |
0.568 |
|
| 2005 |
Kwon H, Jun HS, Yang Y, Mora C, Mariathasan S, Ohashi PS, Flavell RA, Yoon JW. Development of autoreactive diabetogenic T cells in the thymus of NOD mice. Journal of Autoimmunity. 24: 11-23. PMID 15725572 DOI: 10.1016/J.Jaut.2004.10.002 |
0.591 |
|
| 2003 |
Holmberg K, Mariathasan S, Ohteki T, Ohashi PS, Gascoigne NR. TCR binding kinetics measured with MHC class I tetramers reveal a positive selecting peptide with relatively high affinity for TCR. Journal of Immunology (Baltimore, Md. : 1950). 171: 2427-34. PMID 12928390 DOI: 10.4049/Jimmunol.171.5.2427 |
0.594 |
|
| 2001 |
Mariathasan S, Zakarian A, Bouchard D, Michie AM, Zúñiga-Pflücker JC, Ohashi PS. Duration and strength of extracellular signal-regulated kinase signals are altered during positive versus negative thymocyte selection. Journal of Immunology (Baltimore, Md. : 1950). 167: 4966-73. PMID 11673503 DOI: 10.4049/Jimmunol.167.9.4966 |
0.594 |
|
| 2000 |
Oliveira-Dos-Santos AJ, Matsumoto G, Snow BE, Bai D, Houston FP, Whishaw IQ, Mariathasan S, Sasaki T, Wakeham A, Ohashi PS, Roder JC, Barnes CA, Siderovski DP, Penninger JM. Regulation of T cell activation, anxiety, and male aggression by RGS2. Proceedings of the National Academy of Sciences of the United States of America. 97: 12272-7. PMID 11027316 DOI: 10.1073/Pnas.220414397 |
0.574 |
|
| 2000 |
Mariathasan S, Ho SS, Zakarian A, Ohashi PS. Degree of ERK activation influences both positive and negative thymocyte selection. European Journal of Immunology. 30: 1060-8. PMID 10760794 DOI: 10.1002/(Sici)1521-4141(200004)30:4<1060::Aid-Immu1060>3.0.Co;2-2 |
0.583 |
|
| 2000 |
Bachmaier K, Krawczyk C, Kozieradzki I, Kong YY, Sasaki T, Oliveira-dos-Santos A, Mariathasan S, Bouchard D, Wakeham A, Itie A, Le J, Ohashi PS, Sarosi I, Nishina H, Lipkowitz S, et al. Negative regulation of lymphocyte activation and autoimmunity by the molecular adaptor Cbl-b. Nature. 403: 211-6. PMID 10646608 DOI: 10.1038/35003228 |
0.584 |
|
| 1999 |
Mariathasan S, Jones RG, Ohashi PS. Signals involved in thymocyte positive and negative selection Seminars in Immunology. 11: 263-272. PMID 10441212 DOI: 10.1006/Smim.1999.0182 |
0.569 |
|
| 1999 |
Sebzda E, Mariathasan S, Ohteki T, Jones R, Bachmann MF, Ohashi PS. Selection of the T cell repertoire Annual Review of Immunology. 17: 829-874. PMID 10358775 DOI: 10.1146/Annurev.Immunol.17.1.829 |
0.612 |
|
| 1998 |
Kong YY, Fischer KD, Bachmann MF, Mariathasan S, Kozieradzki I, Nghiem MP, Bouchard D, Bernstein A, Ohashi PS, Penninger JM. Vav regulates peptide-specific apoptosis in thymocytes. The Journal of Experimental Medicine. 188: 2099-111. PMID 9841924 DOI: 10.1084/Jem.188.11.2099 |
0.59 |
|
| 1998 |
Mariathasan S, Bachmann MF, Bouchard D, Ohteki T, Ohashi PS. Degree of TCR internalization and Ca2+ flux correlates with thymocyte selection. Journal of Immunology (Baltimore, Md. : 1950). 161: 6030-7. PMID 9834085 |
0.587 |
|
| 1998 |
Liu Q, Oliveira-Dos-Santos AJ, Mariathasan S, Bouchard D, Jones J, Sarao R, Kozieradzki I, Ohashi PS, Penninger JM, Dumont DJ. The inositol polyphosphate 5-phosphatase ship is a crucial negative regulator of B cell antigen receptor signaling. The Journal of Experimental Medicine. 188: 1333-42. PMID 9763612 DOI: 10.1084/Jem.188.7.1333 |
0.581 |
|
| 1997 |
Bachmann MF, Mariathasan S, Bouchard D, Speiser DE, Ohashi PS. Four types of Ca2+ signals in naive CD8+ cytotoxic T cells after stimulation with T cell agonists, partial agonists and antagonists. European Journal of Immunology. 27: 3414-9. PMID 9464830 DOI: 10.1002/Eji.1830271241 |
0.574 |
|
| 1997 |
Bachmann MF, Oxenius A, Speiser DE, Mariathasan S, Hengartner H, Zinkernagel RM, Ohashi PS. Peptide-induced T cell receptor down-regulation on naive T cells predicts agonist/partial agonist properties and strictly correlates with T cell activation. European Journal of Immunology. 27: 2195-203. PMID 9341759 DOI: 10.1002/Eji.1830270912 |
0.624 |
|
| 1996 |
Molina H, Holers VM, Li B, Fang YF, Mariathasan S, Goellner J, Strauss-Schoenberger J, Karr RW, Chaplin DD. Markedly impaired humoral immune response in mice deficient in complement receptors 1 and 2 Proceedings of the National Academy of Sciences of the United States of America. 93: 3357-3361. PMID 8622941 DOI: 10.1073/pnas.93.8.3357 |
0.338 |
|
| Low-probability matches (unlikely to be authored by this person) |
| 2022 |
Salomé B, Sfakianos JP, Ranti D, Daza J, Bieber C, Charap A, Hammer C, Banchereau R, Farkas AM, Ruan DF, Izadmehr S, Geanon D, Kelly G, de Real RM, Lee B, ... ... Mariathasan S, et al. NKG2A and HLA-E define an alternative immune checkpoint axis in bladder cancer. Cancer Cell. 40: 1027-1043.e9. PMID 36099881 DOI: 10.1016/j.ccell.2022.08.005 |
0.299 |
|
| 2022 |
Krishnamurty AT, Shyer JA, Thai M, Gandham V, Buechler MB, Yang YA, Pradhan RN, Wang AW, Sanchez PL, Qu Y, Breart B, Chalouni C, Dunlap D, Ziai J, Elstrott J, ... ... Mariathasan S, et al. LRRC15 myofibroblasts dictate the stromal setpoint to suppress tumour immunity. Nature. PMID 36171287 DOI: 10.1038/s41586-022-05272-1 |
0.298 |
|
| 2021 |
Banchereau R, Chitre AS, Scherl A, Wu TD, Patil NS, de Almeida P, Kadel Iii EE, Madireddi S, Au-Yeung A, Takahashi C, Chen YJ, Modrusan Z, McBride J, Nersesian R, El-Gabry EA, ... ... Mariathasan S, et al. Intratumoral CD103+ CD8+ T cells predict response to PD-L1 blockade. Journal For Immunotherapy of Cancer. 9. PMID 33827905 DOI: 10.1136/jitc-2020-002231 |
0.276 |
|
| 2024 |
Galsky MD, Guan X, Rishipathak D, Rapaport AS, Shehata HM, Banchereau R, Yuen K, Varfolomeev E, Hu R, Han CJ, Li H, Liang Y, Vucic D, Wang L, Zhu J, ... ... Mariathasan S, et al. Immunomodulatory effects and improved outcomes with cisplatin- versus carboplatin-based chemotherapy plus atezolizumab in urothelial cancer. Cell Reports. Medicine. 101393. PMID 38280376 DOI: 10.1016/j.xcrm.2024.101393 |
0.26 |
|
| 2024 |
Guan X, Hu R, Choi Y, Srivats S, Nabet BY, Silva J, McGinnis L, Hendricks R, Nutsch K, Banta KL, Duong E, Dunkle A, Chang PS, Han CJ, Mittman S, ... ... Mariathasan S, et al. Anti-TIGIT antibody improves PD-L1 blockade through myeloid and T cells. Nature. PMID 38418879 DOI: 10.1038/s41586-024-07121-9 |
0.257 |
|
| 2009 |
Munugalavadla V, Berry L, Du C, Mariathasan S, Slaga D, Sun L, Chesi M, Bergsagel PL, Ebens AJ. The PI3K Inhibitor GDC-0941 Synergizes with Standard of Care Therapies to Induce Growth Inhibition and Apoptosis of Multiple Myeloma Cells. Blood. 114: 3788-3788. DOI: 10.1182/BLOOD.V114.22.3788.3788 |
0.247 |
|
| 2016 |
Zhang W, Khojasteh M, Cummins N, Hubbard A, Hurley J, Zhang L, Elgabry E, Bredno J, Harshman D, Day W, Kowanetz M, Mariathasan S, Smith D, Williams JA, Pestic-Dragovich L, et al. Quantitative image analysis of PD-L1, CD8, CD3, CD68 and FoxP3 protein expression in lung and bladder cancer specimens by fully automated multiplex fluorescence immunohistochemistry. Journal of Clinical Oncology. 34: 11590-11590. DOI: 10.1200/Jco.2016.34.15_Suppl.11590 |
0.242 |
|
| 2014 |
Munugalavadla V, Mariathasan S, Slaga D, Du C, Berry L, Del Rosario G, Yan Y, Boe M, Sun L, Friedman LS, Chesi M, Leif Bergsagel P, Ebens A. The PI3K inhibitor GDC-0941 combines with existing clinical regimens for superior activity in multiple myeloma. Oncogene. 33: 316-25. PMID 23318440 DOI: 10.1038/onc.2012.594 |
0.232 |
|
| 2004 |
Mariathasan S, Hewton K, Monack DM, Vucic D, French DM, Lee WP, Roose-Girma M, Erickson S, Dixit VM. Differential activation of the inflammasome by caspase-1 adaptors ASC and Ipaf Nature. 430: 213-218. PMID 15190255 DOI: 10.1038/Nature02664 |
0.228 |
|
| 2017 |
Mariathasan S, Turley S, Nickles D, Castiglioni A, Yuen K, Wang Y, Edward E K, Koeppen H, Astarita J, Cubas R, Jhunjhunwala S, Yang Y, Şenbabaoğlu Y, van der Heijden M, Loriot Y, et al. TGF-β signalling attenuates tumour response to PD-L1 checkpoint blockade by contributing to retention of T cells in the peritumoural stroma Annals of Oncology. 28: xi30. DOI: 10.1093/Annonc/Mdx760.001 |
0.22 |
|
| 2014 |
Sun Y, Caplazi P, Zhang J, Mazloom A, Kummerfeld S, Quinones G, Senger K, Lesch J, Peng I, Sebrell A, Luk W, Lu Y, Lin Z, Barck K, Young J, ... ... Mariathasan S, et al. PILRα negatively regulates mouse inflammatory arthritis. Journal of Immunology (Baltimore, Md. : 1950). 193: 860-70. PMID 24935926 DOI: 10.4049/Jimmunol.1400045 |
0.218 |
|
| 2007 |
Mariathasan S, Monack DM. Inflammasome adaptors and sensors: intracellular regulators of infection and inflammation. Nature Reviews. Immunology. 7: 31-40. PMID 17186029 DOI: 10.1038/Nri1997 |
0.218 |
|
| 2018 |
Mariathasan S, Turley SJ, Nickles D, Castiglioni A, Yuen K, Wang Y, Kadel Iii EE, Koeppen H, Astarita JL, Cubas R, Jhunjhunwala S, Banchereau R, Yang Y, Guan Y, Chalouni C, et al. TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells. Nature. PMID 29443960 DOI: 10.1038/Nature25501 |
0.217 |
|
| 2020 |
Verschueren E, Husain B, Yuen K, Sun Y, Paduchuri S, Senbabaoglu Y, Lehoux I, Arena TA, Wilson B, Lianoglou S, Bakalarski C, Franke Y, Chan P, Wong AW, Gonzalez LC, ... Mariathasan S, et al. The Immunoglobulin Superfamily Receptome Defines Cancer-Relevant Networks Associated with Clinical Outcome. Cell. PMID 32589946 DOI: 10.1016/j.cell.2020.06.007 |
0.215 |
|
| 2022 |
Huseni MA, Wang L, Klementowicz JE, Yuen K, Breart B, Orr C, Liu LF, Li Y, Gupta V, Li C, Rishipathak D, Peng J, Şenbabaoǧlu Y, Modrusan Z, Keerthivasan S, ... ... Mariathasan S, et al. CD8 T cell-intrinsic IL-6 signaling promotes resistance to anti-PD-L1 immunotherapy. Cell Reports. Medicine. 100878. PMID 36599350 DOI: 10.1016/j.xcrm.2022.100878 |
0.208 |
|
| 2006 |
Zamboni DS, Kobayashi KS, Kohlsdorf T, Ogura Y, Long EM, Vance RE, Kuida K, Mariathasan S, Dixit VM, Flavell RA, Dietrich WF, Roy CR. The Birc1e cytosolic pattern-recognition receptor contributes to the detection and control of Legionella pneumophila infection. Nature Immunology. 7: 318-25. PMID 16444259 DOI: 10.1038/Ni1305 |
0.207 |
|
| 2024 |
Guan X, Hu R, Choi Y, Srivats S, Nabet BY, Silva J, McGinnis L, Hendricks R, Nutsch K, Banta KL, Duong E, Dunkle A, Chang PS, Han CJ, Mittman S, ... ... Mariathasan S, et al. Publisher Correction: Anti-TIGIT antibody improves PD-L1 blockade through myeloid and T cells. Nature. PMID 38480897 DOI: 10.1038/s41586-024-07280-9 |
0.206 |
|
| 2006 |
Mariathasan S, Weiss DS, Newton K, McBride J, O'Rourke K, Roose-Girma M, Lee WP, Weinrauch Y, Monack DM, Dixit VM. Cryopyrin activates the inflammasome in response to toxins and ATP. Nature. 440: 228-32. PMID 16407890 DOI: 10.1038/Nature04515 |
0.198 |
|
| 2023 |
Ortiz-Muñoz G, Brown M, Carbone CB, Pechuan-Jorge X, Rouilly V, Lindberg H, Ritter AT, Raghupathi G, Sun Q, Nicotra T, Mantri SR, Yang A, Doerr J, Nagarkar D, Darmanis S, ... ... Mariathasan S, et al. In situ tumour arrays reveal early environmental control of cancer immunity. Nature. PMID 37258670 DOI: 10.1038/s41586-023-06132-2 |
0.196 |
|
| 2010 |
Broz P, Newton K, Lamkanfi M, Mariathasan S, Dixit VM, Monack DM. Redundant roles for inflammasome receptors NLRP3 and NLRC4 in host defense against Salmonella Journal of Experimental Medicine. 207: 1745-1755. PMID 20603313 DOI: 10.1084/Jem.20100257 |
0.191 |
|
| 2005 |
Mariathasan S, Weiss DS, Dixit VM, Monack DM. Innate immunity against Francisella tularensis is dependent on the ASC/caspase-1 axis. The Journal of Experimental Medicine. 202: 1043-9. PMID 16230474 DOI: 10.1084/Jem.20050977 |
0.183 |
|
| 1996 |
Matsumoto M, Lo SF, Carruthers CJL, Min J, Mariathasan S, Huang G, Plas DR, Martin SM, Geha RS, Nahm MH, Chaplin DD. Affinity maturation without germinal centres in lymphotoxin-α- deficient mice Nature. 382: 462-466. PMID 8684487 DOI: 10.1038/382462A0 |
0.182 |
|
| 2020 |
Yuen KC, Liu LF, Gupta V, Madireddi S, Keerthivasan S, Li C, Rishipathak D, Williams P, Kadel EE, Koeppen H, Chen YJ, Modrusan Z, Grogan JL, Banchereau R, Leng N, ... ... Mariathasan S, et al. High systemic and tumor-associated IL-8 correlates with reduced clinical benefit of PD-L1 blockade. Nature Medicine. 26: 693-698. PMID 32405063 DOI: 10.1038/S41591-020-0860-1 |
0.181 |
|
| 1995 |
Mariathasan S, Matsumoto M, Baranyay F, Nahm MH, Kanagawa O, Chaplin DD. Absence of lymph nodes in lymphotoxin-α(LTα)-deficient mice is due to abnormal organ development, not defective lymphocyte migration Journal of Inflammation. 45: 72-78. PMID 7583355 |
0.179 |
|
| 2020 |
Chen J, Madireddi S, Nagarkar D, Migdal M, Vander Heiden J, Chang D, Mukhyala K, Selvaraj S, Kadel EE, Brauer MJ, Mariathasan S, Hunkapiller J, Jhunjhunwala S, Albert ML, Hammer C. In silico tools for accurate HLA and KIR inference from clinical sequencing data empower immunogenetics on individual-patient and population scales. Briefings in Bioinformatics. PMID 32940337 DOI: 10.1093/Bib/Bbaa223 |
0.175 |
|
| 2007 |
Mariathasan S. ASC, Ipaf and Cryopyrin/Nalp3: bona fide intracellular adapters of the caspase-1 inflammasome. Microbes and Infection / Institut Pasteur. 9: 664-71. PMID 17382568 DOI: 10.1016/j.micinf.2007.01.017 |
0.169 |
|
| 2020 |
Motzer RJ, Banchereau R, Hamidi H, Powles T, McDermott D, Atkins MB, Escudier B, Liu LF, Leng N, Abbas AR, Fan J, Koeppen H, Lin J, Carroll S, Hashimoto K, ... Mariathasan S, et al. Molecular Subsets in Renal Cancer Determine Outcome to Checkpoint and Angiogenesis Blockade. Cancer Cell. PMID 33157048 DOI: 10.1016/j.ccell.2020.10.011 |
0.165 |
|
| 1996 |
Danska JS, Holland DP, Mariathasan S, Williams KM, Guidos CJ. Biochemical and genetic defects in the DNA-dependent protein kinase in murine scid lymphocytes Molecular and Cellular Biology. 16: 5507-5517. PMID 8816463 DOI: 10.1128/Mcb.16.10.5507 |
0.155 |
|
| 2008 |
Hsu LC, Ali SR, McGillivray S, Tseng PH, Mariathasan S, Humke EW, Eckmann L, Powell JJ, Nizet V, Dixit VM, Karin M. A NOD2-NALP1 complex mediates caspase-1-dependent IL-1beta secretion in response to Bacillus anthracis infection and muramyl dipeptide. Proceedings of the National Academy of Sciences of the United States of America. 105: 7803-8. PMID 18511561 DOI: 10.1073/Pnas.0802726105 |
0.151 |
|
| 2003 |
Mariathasan S, Vucic D. POPing the fire into the pyrin? The Biochemical Journal. 373: e1-2. PMID 12939166 DOI: 10.1042/BJ20030304COM |
0.142 |
|
| 2019 |
Powles T, Kockx M, Rodriguez-Vida A, Duran I, Crabb SJ, Van Der Heijden MS, Szabados B, Pous AF, Gravis G, Herranz UA, Protheroe A, Ravaud A, Maillet D, Mendez MJ, Suarez C, ... ... Mariathasan S, et al. Clinical efficacy and biomarker analysis of neoadjuvant atezolizumab in operable urothelial carcinoma in the ABACUS trial. Nature Medicine. PMID 31686036 DOI: 10.1038/s41591-019-0628-7 |
0.135 |
|
| 2013 |
Hazenbos WL, Kajihara KK, Vandlen R, Morisaki JH, Lehar SM, Kwakkenbos MJ, Beaumont T, Bakker AQ, Phung Q, Swem LR, Ramakrishnan S, Kim J, Xu M, Shah IM, Diep BA, ... ... Mariathasan S, et al. Novel staphylococcal glycosyltransferases SdgA and SdgB mediate immunogenicity and protection of virulence-associated cell wall proteins. Plos Pathogens. 9: e1003653. PMID 24130480 DOI: 10.1371/Journal.Ppat.1003653 |
0.134 |
|
| 1996 |
Matsumoto M, Mariathasan S, Nahm MH, Baranyay F, Peschon JJ, Chaplin DD. Role of lymphotoxin and the type I TNF receptor in the formation of germinal centers Science. 271: 1289-1291. PMID 8638112 DOI: 10.1126/Science.271.5253.1289 |
0.128 |
|
| 2020 |
Khan Z, Di Nucci F, Kwan A, Hammer C, Mariathasan S, Rouilly V, Carroll J, Fontes M, Ley Acosta S, Guardino E, Chen-Harris H, Bhangale T, Mellman I, Rosenberg J, Powles T, et al. Polygenic risk for skin autoimmunity impacts immune checkpoint blockade in bladder cancer. Proceedings of the National Academy of Sciences of the United States of America. PMID 32430334 DOI: 10.1073/Pnas.1922867117 |
0.118 |
|
| 2014 |
De Togni P, Goellner J, Ruddle NH, Streeter PR, Andrea F, Mariathasan S, Smith SC, Carlson R, Shornick LP, Strauss-Schoenberger J, Russell JH, Karr R, Chaplin DD. Pillars article: Abnormal development of peripheral lymphoid organs in mice deficient in lymphotoxin. Science. 1994. 264: 703-707. Journal of Immunology (Baltimore, Md. : 1950). 192: 2010-4. PMID 24563504 |
0.117 |
|
| 2021 |
Banchereau R, Leng N, Zill O, Sokol E, Liu G, Pavlick D, Maund S, Liu LF, Kadel E, Baldwin N, Jhunjhunwala S, Nickles D, Assaf ZJ, Bower D, Patil N, ... ... Mariathasan S, et al. Molecular determinants of response to PD-L1 blockade across tumor types. Nature Communications. 12: 3969. PMID 34172722 DOI: 10.1038/s41467-021-24112-w |
0.116 |
|
| 1996 |
Shornick LP, De Togni P, Mariathasan S, Goellner J, Strauss-Schoenberger J, Karr RW, Ferguson TA, Chaplin DD. Mice deficient in IL-1beta manifest impaired contact hypersensitivity to trinitrochlorobenzone. The Journal of Experimental Medicine. 183: 1427-36. PMID 8666901 DOI: 10.1084/Jem.183.4.1427 |
0.115 |
|
| 2018 |
Lim YW, Chen-Harris H, Mayba O, Lianoglou S, Wuster A, Bhangale T, Khan Z, Mariathasan S, Daemen A, Reeder J, Haverty PM, Forrest WF, Brauer M, Mellman I, Albert ML. Germline genetic polymorphisms influence tumor gene expression and immune cell infiltration. Proceedings of the National Academy of Sciences of the United States of America. PMID 30463956 DOI: 10.1073/Pnas.1804506115 |
0.114 |
|
| 2018 |
Fong R, Kajihara K, Chen M, Hotzel I, Mariathasan S, Hazenbos WLW, Lupardus PJ. Structural investigation of human S. aureus-targeting antibodies that bind wall teichoic acid. Mabs. PMID 30102105 DOI: 10.2210/Pdb6Dwi/Pdb |
0.106 |
|
| 1994 |
Chaplin D, Mariathasan S, De Togni P, Kanagawa O. Absence of lymph nodes in lymphotoxin-α (LTα)-deficient mice reflects dysfunction during development, not disturbed lymphocyte migration Cytokine. 6: 573. DOI: 10.1016/1043-4666(94)90287-9 |
0.106 |
|
| 2015 |
Lehar SM, Pillow T, Xu M, Staben L, Kajihara KK, Vandlen R, DePalatis L, Raab H, Hazenbos WL, Hiroshi Morisaki J, Kim J, Park S, Darwish M, Lee BC, Hernandez H, ... ... Mariathasan S, et al. Novel antibody-antibiotic conjugate eliminates intracellular S. aureus. Nature. PMID 26536114 DOI: 10.1038/Nature16057 |
0.106 |
|
| 2022 |
Yuen KC, Tran B, Anton A, Hamidi H, Costello AJ, Corcoran NM, Lawrentschuk N, Rainey N, Semira MCG, Gibbs P, Mariathasan S, Sandhu S, Kadel EE. Molecular classification of hormone-sensitive and castration-resistant prostate cancer, using nonnegative matrix factorization molecular subtyping of primary and metastatic specimens. The Prostate. PMID 35435276 DOI: 10.1002/pros.24346 |
0.105 |
|
| 2021 |
Powles T, Assaf ZJ, Davarpanah N, Banchereau R, Szabados BE, Yuen KC, Grivas P, Hussain M, Oudard S, Gschwend JE, Albers P, Castellano D, Nishiyama H, Daneshmand S, Sharma S, ... ... Mariathasan S, et al. ctDNA guiding adjuvant immunotherapy in urothelial carcinoma. Nature. PMID 34135506 DOI: 10.1038/s41586-021-03642-9 |
0.104 |
|
| 2018 |
Vennapusa B, Baker B, Kowanetz M, Boone J, Menzl I, Bruey JM, Fine G, Mariathasan S, McCaffery I, Mocci S, Rost S, Smith D, Dennis E, Tang SY, Damadzadeh B, et al. Development of a PD-L1 Complementary Diagnostic Immunohistochemistry Assay (SP142) for Atezolizumab. Applied Immunohistochemistry & Molecular Morphology : Aimm. PMID 29346180 DOI: 10.1097/PAI.0000000000000594 |
0.096 |
|
| 2020 |
Wagle MC, Castillo J, Srinivasan S, Holcomb T, Yuen KC, Kadel EE, Mariathasan S, Halligan DL, Carr AR, Bylesjo M, McAdam PR, Lynagh S, Marien KM, Kockx M, Waumans Y, et al. Tumor Fusion Burden as a hallmark of immune infiltration in prostate cancer. Cancer Immunology Research. PMID 32321776 DOI: 10.1158/2326-6066.CIR-19-0568 |
0.094 |
|
| 2016 |
Zhou C, Lehar S, Gutierrez J, Rosenberger CM, Ljumanovic N, Dinoso J, Koppada N, Hong K, Baruch A, Carrasco-Triguero M, Saad O, Mariathasan S, Kamath AV. Pharmacokinetics and pharmacodynamics of DSTA4637A: A novel Thiomab™-antibiotic conjugate against Staphylococcus aureus in mice. Mabs. 0. PMID 27653831 DOI: 10.1080/19420862.2016.1229722 |
0.093 |
|
| 2016 |
Staben LR, Koenig SG, Lehar SM, Vandlen R, Zhang D, Chuh J, Yu SF, Ng C, Guo J, Liu Y, Fourie-O'Donohue A, Go M, Linghu X, Segraves NL, Wang T, ... ... Mariathasan S, et al. Targeted drug delivery through the traceless release of tertiary and heteroaryl amines from antibody-drug conjugates. Nature Chemistry. 8: 1112-1119. PMID 27874860 DOI: 10.1038/Nchem.2635 |
0.089 |
|
| 2022 |
Powles T, Yuen KC, Gillessen S, Kadel EE, Rathkopf D, Matsubara N, Drake CG, Fizazi K, Piulats JM, Wysocki PJ, Buchschacher GL, Alekseev B, Mellado B, Karaszewska B, Doss JF, ... ... Mariathasan S, et al. Atezolizumab with enzalutamide versus enzalutamide alone in metastatic castration-resistant prostate cancer: a randomized phase 3 trial. Nature Medicine. PMID 35013615 DOI: 10.1038/s41591-021-01600-6 |
0.088 |
|
| 2017 |
Mariathasan S, Tan MW. Antibody-Antibiotic Conjugates: A Novel Therapeutic Platform against Bacterial Infections. Trends in Molecular Medicine. PMID 28126271 DOI: 10.1016/J.Molmed.2016.12.008 |
0.08 |
|
| 2016 |
Rosenberg JE, Hoffman-Censits J, Powles T, van der Heijden MS, Balar AV, Necchi A, Dawson N, O'Donnell PH, Balmanoukian A, Loriot Y, Srinivas S, Retz MM, Grivas P, Joseph RW, Galsky MD, ... ... Mariathasan S, et al. Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial. Lancet (London, England). PMID 26952546 DOI: 10.1016/S0140-6736(16)00561-4 |
0.075 |
|
| 2021 |
Yuen KC, Liu LF, Gupta V, Madireddi S, Keerthivasan S, Li C, Rishipathak D, Williams P, Kadel EE, Koeppen H, Chen YJ, Modrusan Z, Grogan JL, Banchereau R, Leng N, ... ... Mariathasan S, et al. Author Correction: High systemic and tumor-associated IL-8 correlates with reduced clinical benefit of PD-L1 blockade. Nature Medicine. PMID 33547461 DOI: 10.1038/s41591-021-01246-4 |
0.07 |
|
| 2017 |
Ackerman C, Mariathasan S, Nickles D, Gomez De Liano Lista A, Wimalasingham AG, Szabados B, Powles T. Molecular subtyping of metastatic urothelial bladder cancer. Journal of Clinical Oncology. 35: 326-326. DOI: 10.1200/JCO.2017.35.6_suppl.326 |
0.065 |
|
| 2016 |
Balar AV, Galsky MD, Rosenberg JE, Powles T, Petrylak DP, Bellmunt J, Loriot Y, Necchi A, Hoffman-Censits J, Perez-Gracia JL, Dawson NA, van der Heijden MS, Dreicer R, Srinivas S, Retz MM, ... ... Mariathasan S, et al. Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial. Lancet (London, England). PMID 27939400 DOI: 10.1016/S0140-6736(16)32455-2 |
0.059 |
|
| 2010 |
Broz P, Lamkanfi M, Newton K, Mariathasan S, Dixit V, Monack D. E11 Multiple inflammasomes direct innate immune responses against Salmonella Journal of Crohn's and Colitis Supplements. 4: 9. DOI: 10.1016/S1873-9954(10)70015-X |
0.055 |
|
| 2023 |
Powles T, Assaf ZJ, Degaonkar V, Grivas P, Hussain M, Oudard S, Gschwend JE, Albers P, Castellano D, Nishiyama H, Daneshmand S, Sharma S, Sethi H, Aleshin A, Shi Y, ... ... Mariathasan S, et al. Updated Overall Survival by Circulating Tumor DNA Status from the Phase 3 IMvigor010 Trial: Adjuvant Atezolizumab Versus Observation in Muscle-invasive Urothelial Carcinoma. European Urology. PMID 37500339 DOI: 10.1016/j.eururo.2023.06.007 |
0.047 |
|
| 2017 |
Powles T, Durán I, van der Heijden MS, Loriot Y, Vogelzang NJ, De Giorgi U, Oudard S, Retz MM, Castellano D, Bamias A, Fléchon A, Gravis G, Hussain S, Takano T, Leng N, ... ... Mariathasan S, et al. Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial. Lancet (London, England). PMID 29268948 DOI: 10.1016/S0140-6736(17)33297-X |
0.046 |
|
| 2023 |
Bamias A, Davis ID, Galsky MD, Arranz JÁ, Kikuchi E, Grande E, Del Muro XG, Park SH, De Giorgi U, Alekseev B, Mencinger M, Izumi K, Schutz FA, Puente J, Li JR, ... ... Mariathasan S, et al. Atezolizumab monotherapy versus chemotherapy in untreated locally advanced or metastatic urothelial carcinoma (IMvigor130): final overall survival analysis from a randomised, controlled, phase 3 study. The Lancet. Oncology. PMID 38101431 DOI: 10.1016/S1470-2045(23)00539-9 |
0.044 |
|
| 2021 |
Petrylak DP, Loriot Y, Shaffer D, Braiteh F, Powderly J, Harshman LC, Conkling P, Delord JP, Gordon M, Kim JW, Sarkar I, Yuen KC, Kadel EE, Mariathasan S, O'Hear C, et al. Safety and Clinical Activity of Atezolizumab in Patients With Metastatic Castration-Resistant Prostate Cancer: a Phase I Study. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 33568344 DOI: 10.1158/1078-0432.CCR-20-1981 |
0.044 |
|
| 2016 |
Rosenberg JE, Petrylak DP, Van Der Heijden MS, Necchi A, O'Donnell PH, Loriot Y, Retz M, Perez-Gracia JL, Bellmunt J, Grivas P, Joseph RW, Fong L, Kadel EE, Boyd Z, Nickles D, ... ... Mariathasan S, et al. PD-L1 expression, Cancer Genome Atlas (TCGA) subtype, and mutational load as independent predictors of response to atezolizumab (atezo) in metastatic urothelial carcinoma (mUC; IMvigor210). Journal of Clinical Oncology. 34: 104-104. DOI: 10.1200/JCO.2016.34.15_SUPPL.104 |
0.042 |
|
| 2023 |
Powles T, Young A, Nimeiri H, Madison RW, Fine A, Zollinger DR, Huang Y, Xu C, Gjoerup OV, Aushev VN, Wu HT, Aleshin A, Carter C, Davarpanah N, Degaonkar V, ... ... Mariathasan S, et al. Molecular residual disease detection in resected, muscle-invasive urothelial cancer with a tissue-based comprehensive genomic profiling-informed personalized monitoring assay. Frontiers in Oncology. 13: 1221718. PMID 37601688 DOI: 10.3389/fonc.2023.1221718 |
0.033 |
|
| 2023 |
Grande E, Arranz JÁ, De Santis M, Bamias A, Kikuchi E, Del Muro XG, Park SH, De Giorgi U, Alekseev B, Mencinger M, Izumi K, Schutz FA, Puente J, Li JR, O'Donnell PH, ... ... Mariathasan S, et al. Atezolizumab plus chemotherapy versus placebo plus chemotherapy in untreated locally advanced or metastatic urothelial carcinoma (IMvigor130): final overall survival analysis results from a randomised, controlled, phase 3 study. The Lancet. Oncology. PMID 38101433 DOI: 10.1016/S1470-2045(23)00540-5 |
0.033 |
|
| 2023 |
Inman BA, Hahn NM, Stratton K, Kopp R, Sankin A, Skinner E, Pohar K, Gartrell BA, Pham S, Rishipathak D, Mariathasan S, Davarpanah N, Carter C, Steinberg GD. A Phase 1b/2 Study of Atezolizumab with or Without Bacille Calmette-Guérin in Patients with High-risk Non-muscle-invasive Bladder Cancer. European Urology Oncology. PMID 36803840 DOI: 10.1016/j.euo.2023.01.013 |
0.029 |
|
| 2020 |
Galsky MD, Arija JÁA, Bamias A, Davis ID, De Santis M, Kikuchi E, Garcia-Del-Muro X, De Giorgi U, Mencinger M, Izumi K, Panni S, Gumus M, Özgüroğlu M, Kalebasty AR, Park SH, ... ... Mariathasan S, et al. Atezolizumab with or without chemotherapy in metastatic urothelial cancer (IMvigor130): a multicentre, randomised, placebo-controlled phase 3 trial. Lancet (London, England). 395: 1547-1557. PMID 32416780 DOI: 10.1016/S0140-6736(20)30230-0 |
0.017 |
|
| 2021 |
Bellmunt J, Hussain M, Gschwend JE, Albers P, Oudard S, Castellano D, Daneshmand S, Nishiyama H, Majchrowicz M, Degaonkar V, Shi Y, Mariathasan S, Grivas P, Drakaki A, O'Donnell PH, et al. Adjuvant atezolizumab versus observation in muscle-invasive urothelial carcinoma (IMvigor010): a multicentre, open-label, randomised, phase 3 trial. The Lancet. Oncology. PMID 33721560 DOI: 10.1016/S1470-2045(21)00004-8 |
0.013 |
|
| 2022 |
Szabados B, Kockx M, Assaf ZJ, van Dam PJ, Rodriguez-Vida A, Duran I, Crabb SJ, Van Der Heijden MS, Pous AF, Gravis G, Herranz UA, Protheroe A, Ravaud A, Maillet D, Mendez MJ, ... ... Mariathasan S, et al. Final Results of Neoadjuvant Atezolizumab in Cisplatin-ineligible Patients with Muscle-invasive Urothelial Cancer of the Bladder. European Urology. PMID 35577646 DOI: 10.1016/j.eururo.2022.04.013 |
0.013 |
|
| 2023 |
Powles T, Kockx M, Rodriguez-Vida A, Duran I, Crabb SJ, Van Der Heijden MS, Szabados B, Pous AF, Gravis G, Herranz UA, Protheroe A, Ravaud A, Maillet D, Mendez MJ, Suarez C, ... ... Mariathasan S, et al. Publisher Correction: Clinical efficacy and biomarker analysis of neoadjuvant atezolizumab in operable urothelial carcinoma in the ABACUS trial. Nature Medicine. PMID 36944799 DOI: 10.1038/s41591-023-02312-9 |
0.01 |
|
| 2020 |
Powles T, Kockx M, Rodriguez-Vida A, Duran I, Crabb SJ, Van Der Heijden MS, Szabados B, Pous AF, Gravis G, Herranz UA, Protheroe A, Ravaud A, Maillet D, Mendez MJ, Suarez C, ... ... Mariathasan S, et al. Publisher Correction: Clinical efficacy and biomarker analysis of neoadjuvant atezolizumab in operable urothelial carcinoma in the ABACUS trial. Nature Medicine. 26: 983. PMID 32555515 DOI: 10.1038/s41591-020-0923-3 |
0.01 |
|
| Hide low-probability matches. |